Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628251 · ClinicalTrials.gov registry record · Phase 2
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT00628251 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 97 participants.
The verdict
NCT00628251, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.
Interventions
- DRUG Liposomal Doxorubicin
- DRUG AZD2281
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2008-07-30 |
| Est. Completion | 2018-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00628251
The ClinicalTrials.gov registry entry for NCT00628251 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Doxorubicin is the first listed.
NCT00628251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00628251 about?
NCT00628251 is a clinical study titled "Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer". The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.
What is the current status of trial NCT00628251?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2008-07-30. Estimated completion is 2018-09-19.
What interventions are being tested in trial NCT00628251?
The interventions under investigation include: Liposomal Doxorubicin (DRUG), AZD2281 (DRUG).
Who is sponsoring clinical trial NCT00628251?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.